-
-
- Targeted therapies
- Targeted biologics
- Precision immuno-oncology
- Cell & gene therapies
- Radiotheranostics / targeted radionuclide therapies
- Combination regimens
-
- Companion diagnostics (CDx)
- Complementary diagnostics
- Comprehensive genomic profiling (CGP) panels
- Minimal residual disease (MRD) testing
- Pharmacogenomics (PGx) relevant to oncology regimens
-
- Clinical decision support (CDS) / treatment matching engines
- Variant interpretation & annotation platforms
- Molecular tumor board (MTB) enablement software
- Data integration (EHR/LIS/omics) & interoperability tools
-
- Sample logistics, biobanking, and pre-analytics services
- Bioinformatics services (pipeline, interpretation, reporting)
- Clinical trial matching services
- Real-world evidence (RWE) and outcomes analytics
- Contract research / companion diagnostic development services
-
- Risk assessment & screening
- Diagnosis & tumor classification
- Therapy selection
- Treatment monitoring
- Response monitoring
- Resistance emergence detection
- Dose/therapy optimization
- Recurrence surveillance / MRD
- Clinical trial enrolment & matching
-
- Genomics
- Next-generation sequencing (NGS)
- Targeted panels
- Whole exome sequencing (WES)
- Whole genome sequencing (WGS)
- PCR / qPCR / ddPCR
- Sanger sequencing (confirmatory)
- Transcriptomics
- RNA sequencing (RNA-seq)
- Gene expression profiling / signatures
- Proteomics / Protein biomarkers
- Immunohistochemistry (IHC)
- Mass spectrometry–based proteomics (select settings)
- Cytogenetics & Structural Variation
- FISH
- Karyotyping (certain hematologic cancers)
- Epigenetics
- DNA methylation profiling (select tumors)
- Liquid biopsy technologies
- ctDNA / cfDNA
- CTCs
- Exosomes / extracellular vesicles (emerging)
- Single-cell & spatial
- Single-cell sequencing (scRNA/scDNA)
- Spatial transcriptomics / multiplex imaging
-
- Genetic biomarkers
- Single nucleotide variants (SNVs)
- Indels
- Copy number variations (CNVs)
- Gene fusions / rearrangements
- Germline variants (hereditary cancer)
- Genomic signatures / global markers
- Tumor mutational burden (TMB)
- Microsatellite instability (MSI)
- Homologous recombination deficiency (HRD)
- Expression / protein markers
- Receptor status, ligand expression, immune markers (e.g., checkpoint pathway expression classes)
- Epigenetic biomarkers
- MRD biomarkers
- Personalized tumor-informed MRD
- Tumor-naïve MRD panels
-
- Tissue-based
- FFPE tissue
- Fresh frozen tissue
- Core needle biopsy / surgical specimens
- Blood-based (liquid biopsy)
- Plasma (ctDNA/cfDNA)
- Whole blood (CTCs, RNA)
- Other biofluids
- Urine, saliva, CSF (indication-dependent)
- Cytology samples
- FNA, smears (select workflows)
-
- Hospitals & cancer centers
- Diagnostic laboratories
- Clinical pathology labs
- Molecular/genetic labs
- Academic & research institutes
- Pharmaceutical & biotech companies
- CROs / clinical trial networks
- Payers / HTA bodies
-
- Solid tumors
- Lung, breast, colorectal, prostate, ovarian, melanoma, pancreatic, gastric, head & neck, liver, kidney, brain/CNS, etc.
- Hematologic malignancies
- Leukemia, lymphoma, myeloma, MDS/MPN, etc.
- Rare cancers / tumor-agnostic segments
- Tumor-agnostic biomarker-defined populations
-
- Public reimbursement
- Private reimbursement
- Out-of-pocket / self-pay
- Hybrid coverage models
- Patient assistance / access programs
- Clinical trial–funded testing
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
